| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3505 |
| Trial ID | NCT05938725 |
| Disease | Lupus Nephritis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KYV-101 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | KYSA-1: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
| Year | 2023 |
| Country | United States |
| Company sponsor | Kyverna Therapeutics |
| Other ID(s) | KYSA-1|KYV101-001 |
| Cohort 1 | |||||||||||
|
|||||||||||